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Cancer chemotherapy occupies the leading posi-
tion in treatment of cancer patients, but an absence 
of selectivity of action of the majority of anticancer 
drugs and often an expressed resistance of tumor 
cells to performed chemotherapy remains a major 
challenge for clinical oncology limiting successful 
therapy of cancer patients.
There are numerous approaches for elevation of the 
efficacy of medicinal preparation action, in particular, the 
development of new technologies for creation of sys-
tems for directed transport of cancer drugs. Liposomes, 
especially spatially stabilized ones, are considered 
optimal variants of carriers used for targeted delivery of 
medicinal preparations to tumor cells. Such liposomes 
acquire the property to enter easily solid tumors through 
the walls of newly developed during neoangiogenesis 
vasculature and, being accumulated there, to act as 
a system constantly releasing medicinal preparations 
[1–3], what is considered in the literature [4] as an effect 
of elevated vessel permeability (EPR-effect). In a num-
ber of experimental studies it has been demonstrated 
higher accumulation of liposomal anticancer drugs in 
cells compared to their free forms [5]. The use of liposo-
mal forms of anticancer drugs in modern chemotherapy 
created an alternative approach that from one side, al-
lows decrease significantly total toxic influence due to 
their selective accumulation in tumor tissue, and from 
other side, — to elevate antitumor effect. Protrac tedly 
circulating liposomes and other macromolecular carriers 
may increase drug depositing in tumors [6].
If anticancer drugs are included into liposomes, 
their distribution in body significantly decreases; while 
their concentration in tumor increases, thus unspecific 
toxicity is lower [7].
There are the data showing that liposomal systems 
of drug delivery may overcome an activity of trans-
port proteins of multiple drug resistance (MDR) even 
in highly resistant tumors. By endocytosis, liposomes 
deliver the preparation in cytoplasm and its direct in-
teraction with P-glycoprotein (P-gp) located in plasma 
membrane is decreased. According to observations 
of Michieli et al. [8], incubation of cells with MDR 
patterns and P-gp hyperexpression with liposomal 
daunorubicin inserted into membrane composed from 
phosphotidylcholine/cholesterol, led to its significant 
intracellular accumulation compared with its free 
form and to 4–5-fold increase of cytotoxic effect. The 
mechanism of such action is not studied completely 
yet. However, experimental data evidence that MDR of 
cells modulated by P-gp, may be altered significantly 
by optimally designed liposome composition and 
inserted cancer drugs [9, 10]. The results of in vitro 
studies and clinical studies with the use of liposomal 
doxorubicin have shown that drug resistance may 
be partially reversed if one would use liposomal form 
of doxorubicin or other cancer grugs [11–13].
Cisplatin and doxorubicin are widely used for 
thera py of cancer patients, but differ in their mecha-
nism of action. It has been demonstrated that the 
use of liposomal forms of the drugs is beneficial to 
their conventional analogs. Despite multiplicity of 
fundamental studies directed on the research of pe-
culiarities of interaction between liposomal forms of 
anticancer drugs with cells, presently many questions 
remain unanswered. There is no data on the character 
of alterations of cells sensitive to cytotoxic action of 
anticancer drugs, after their treatment with liposomal 
analogs versus that of the cells resistant to antican-
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ment of drug resistance, the cells became somewhat 
larger, and on their surface one could see an appear-
ance of expressed protrusions of plasma membrane 
and increased number of microvilli of different length. 
MCF-7/Dox cells possess more spread shape what 
may be observed during their examination by light 
microscopy. With the use of electron microscopy it 
has been detected that cell nuclei are characterized 
by appearance of notable regions of heterochromatin 
located close to inner side of nuclear membrane, and 
by altered shape. The majority of cells possess rug-
ged shape of nucleus due to appearance of nuclear 
membrane invaginations that respectively increase 
its area (Fig. 1, b). Such patterns were not observed 
in drug-sensitive cells. In nucleus one or sometimes 
two nucleoli located on periphery are detected. Cells 
of MCF-7/DDP and MCF-7/Dox sublines are cha-
racterized by higher density what is related to a large 
number of free ribosomes that tend to aggregate with 
the formation of polysomes. High electronic density 
is also related to big quantity of glycogen that forms 
characteristic rosettes all around cytoplasm. One may 
detect the increase of the number of all cell organelles. 
Mitochondria possessing the structure analogous to 
that of original MCF-7 cells, are located throughout 
cell perimeter, sometimes forming small aggregations 
close to nuclear invaginations. During development of 
drug resistance GER also underwent alterations and 
occupies large area in cells and is presented by long 
channels with significant number of ribosomes on its 
outer membranes. One should point on a partial vacuo-
lization of channels tubules in some cells that may be 
related to increased protein synthesis [18].
a
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Fig. 1. Ultrastructure of MCF-7 cells: (a) parental cells, which 
are sensitive to cytotoxic action of antitumor drugs, x 6900; (b) 
variant with acquired resistance to doxorubicin, x 8400
Golgi complex in the majority of cells is composed 
from 2–3 loci placed in one region of cytoplasm, not 
far from nucleus. Each locus has a large number of 
microvesicles that from one side, are bound to few 
flat cisterns, and from other side — with large enough 
vacuoles. The presence of well developed numerous 
structural components of the complex in resistant 
cells vs sensitive MCF-7 cells evidences on functional 
loading of this cell organelle [19]. Using immunocyto-
chemical analysis of resistant cells, Molinari et al. [21] 
have been shown that P-gp was present not only on the 
surface of plasma membrane, but was also located in 
cytoplasm, in particular on vesicles of Golgi complex 
and lyzosomal system components [20], but not on 
mitochondrial membranes.
In cytoplasm of MCF-7/DDP and MCF-7/Dox cells, 
one may detect also a big number of lyzosome-like 
formations, electron-transparent vesicles of different 
size, and lipid inclusions in some cells. It’s necessary 
to note the presence of some cell polymorphism that 
was observed in parental MCF-7 cell line as well.
So, ultrastructure of resistant cells evidences on 
elevation of synthetic processes in the cells (increased 
number of free ribosomes and their aggregation in 
polysomes, higher numbers of GER components and 
elements of Golgi complex). The data point on altera-
tion of cell metabolism that causes modification of their 
architecture [22, 23].
Ultrastructural changes in MCF-7 cells caused 
by action of conventional and liposomal forms of 
cisplatin and doxorubicin. Alterations of parental vari-
ant of MCF-7 cells caused by treatment with conventional 
forms of cisplatin (DDP) and doxorubicin (Dox) were 
of similar character but differ by the degree of expression 
of toxic manifestations. Оur study has shown that paren-
tal MCF-7 cells are more sensitive to Dox that causes 
more expressed cytotoxic alterations than DDP does.
In the majority of cells dystrophic changes were 
detected that were expressed in significant vacuoli-
zation of cell cytoplasm and decrease of the number 
of cytoplasmic organelles. Some cells were in a state 
of necrobiosis, with significant nuclear alterations, in 
particular, with loosen euchromatin, while cytoplasm 
contained a big number of vacuoles of various sizes 
(Fig. 2, а). There were found the cells in necrotic state 
where integrity of cell membrane was disturbed, and 
cytoplasm components were disorganized. The num-
ber of cells with significant toxic manifestations was 
higher in the case of Dox treatment than that of DDP 
treatment. In the majority of studied cells nuclei with 
low electronic density and cytoplasm with large num-
ber of vacuoles and dense single mitochondria were 
observed, while clear detection of other organelles 
was problematic (Fig. 2, b).
Apoptotic cell death upon the action of conventional 
forms of the preparations was more characteristic for 
cells treated with doxorubicin, where all stages of apop-
tosis (from initial cytoplasm and nuclei condensation 
to formation of apoptotic bodies) have been observed. 
DDP Action also led to apoptosis of small part of sensitive 
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cells, but here the quantitative domination of irrevers-
ibly altered cells and cells in necrobisis state have been 
detected. Potential mechanism of cell death upon DDP 
influence is thought to be apoptosis that develops due 
to interaction of DDP with cell DNA; however, in some 
cases at early stages of apoptosis initiation, damage 
of cytoplasmic proteins occurs as well leading to necrotic 
damage of cells [24]. Despite the fact that apoptosis and 
necrosis are the forms of cell death differing by morpho-
logical and biochemical patterns, both their types may 
be present simultaneously in tissues and cultured cells 
upon the action of DDP [25]. The degree of intracellular 
damage caused by DDP may affect the form of cell death 
as a result of necrosis or not fulfilled apoptotic program, 
i. e. cell death induced by DDP not always responds to 
“classic” apoptosis, where an important role is played 
by preparation dose and cell cycle phase at the moment 
of DDP treatment [26].
Action of Dox in the majority of cases leads to 
development of apoptosis which efficacy depends 
on the dose of the preparation and incubation period.
Action of liposomal drugs on parental MCF-7 cells 
also led to death of a part of the cells. A number of cells 
that died upon the action of liposomal forms of the pre-
parations, has increased at average by 3–5%, and also in 
the majority of cells significant cytotoxic alterations that 
manifest themselves in dystrophy of different degree, 
have appeared. It’s necessary to note that cells became 
bigger, possibly, because of expressed vacuolarization 
of cytoplasm (Fig. 2, c). Dystrophic cell changes are also 
expressed in damaged structure of mitochondria which 
number decreased. Cristae deformation and their lower 
numbers are related to lower activity of mitochondria. 
Apart from this, vacuolization of the part of mitochondria 
was detected, pointing on cell autolysis. GER is presented 
by widened cisterns, on which surface there is a moder-
ate number of ribosomes. A part of cells died due to 
necrosis. Upon the action of DDP-Lip there was observed 
a characteristic dominance of expressed dystrophic 
processes that finally lead to cell death, while apoptotic 
cells are rarely observed. For Dox-Lip there was detected 
a characteristic dominance of cells with morphologic 
signs of apoptosis (Fig. 2, d).
Thus, upon the action of liposomal forms of the 
anticancer drugs which concentration is equal to that 
of conventional forms, on drug-sensitive MCF-7 cells, 
one may detect more expressed cytotoxic damage of 
cell components, elevated apoptosis rate, especially in 
the case of Dox-Lip, compared to conventional forms. 
Such effect may be related to higher accumulation 
of liposomal drugs compared to conventional forms 
as well as their different intracellular distribution [6].
Ultrastructural changes of resistant MCF-7 
cells caused by action of conventional and liposo-
mal forms of cisplatin and doxorubicin. Alteration 
of ultrastructure of MCF-7/DDP cells upon the action 
of DDP manifested themselves by the presence of dys-
trophy signs: one could detect a large number of cells 
with electron-transparent vacuoles (Fig. 3, а). In a part 
of cells significant changes related to disorganization of 
all cell components and cytoplasmic matrix evidencing 
on cytotoxic damage, have been detected. Cell sur-
face was bigger via formation of multiple cytoplasmic 
bubbles bound to membrane. The number of apoptotic 
cells was insignificant similarly to that of sensitive MCF-7 
cells. Homotypic changes of resistant and sensitive cells 
treated with conventional form of the preparation may be 
explained by its concentration (IC10 for all studied cells).
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Fig. 2. Changes in ultrastructure of MCF-7 cells, which are 
sensitive to the cytotoxic action of antitumor drugs: (a) influ-
ence of DDP, x 5000; (b) influence of Dox, x 3300; (c) influence 
of DDP-Lip, x 5000; (d) influence of Dox-Lip, x 3300
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Fig. 3. Changes in ultrastructure of MCF-7/DDP and MCF-7/Dох 
cells upon the influence of antitumor drugs: (a) influence of free 
DDP on MCF-7/DDP cells, x 5000; (b) influence of DDP-Lip on 
MCF-7/DDP cells, x 5000; (c) influence of Dox on MCF-7/Dох 
cells, x 15 000; (d) influence of Dox-Lip on MCF-7/Dох cells, x 3000
Upon the influence of DDP-Lip toxic patterns are re-
lated not only to cytoplasm, but to nuclear ultrastructure 
where loosen euchromatin could be detected. In nucle-
oli, granular and dense fibrillar components presented 
by RNA-containing ribosome subunits, were domina-
ting. In cytoplasm of the majority of cells disorganization 
of cell organelles occurred, electron-transparent area 
in cytoplasm appeared, vacuolization of cytoplasm and 
mitochondria were detected (Fig. 3, b). So, treatment of 
resistant cells with DDP-Lip led to more expressive toxic 
effect than that with conventional form of the drugs at 
equal concentration (IC10) did.
Changes of doxorubicin-resistant cells upon the 
influence of Dox evidence on the presence of dystro-
phy of various degrees — cytoplasm disorganization, 
altered density of cytoplasmic matrix, vacuolization 
of cytoplasm, mitochondria, and Goldgi complex 
(Fig. 3, c). Electron-microscopic changes of nuclei 
were characterized by altered chromatin structure that 
was dispersed in nucleus as small granules without 
formation of characteristic aggregation along nuclear 
membrane. Experimental studies performed in vitro 
by other authors with the use of confocal microscopy, 
have shown that in resistant ovarian cancer cells of 
SKVLB line and MCF-7/ADR cells, doxorubicin is loca-
lized and transported mainly by cytoplasmic vesicles. 
The fact that in sensitive cells the preparation may have 
in part nuclear localization, what possibly determines 
its higher cell toxicity, is very important. Intraliposomal 
preservation of doxorubicin alters its distribution in 
resistant cells with partial transfer to nuclear compart-
ments. So, liposomal doxorubicin may enter the cells 
with MDR phenotype bypassing vesicular transport 
and increasing its anticancer activity [27].
An influence of Dox-Lip on doxorubicin-resistant 
cells led to elevation of its toxic effect resulting in 
acceleration of dystrophic processes in cells, and 
increased number of cells in necrobiosis state with 
the tendency to necrotic death. It’s necessary to note 
that among the majority of dying cells, all stages of 
apoptosis have been detected (Fig. 3, d).
The performed electron-microscopic study has 
shown that common cytomorphological manifesta-
tions evidencing on toxic effect of studied cancer 
drugs, account dystrophic alterations in cytoplasm, 
nucleus, and cell organelles, and also death of the 
part of cells by necrosis and apoptosis, what is more 
notable in the case of treatment with liposomal phar-
maceutical forms, especially Dox-Lip.
In total, evaluating an effect of action of equal con-
centrations of cisplatin and doxorubicin in conventional 
and liposomal forms, one may conclude on higher 
cytotoxic action of doxorubicin vs cisplatin that is ex-
pressed in a wider spectrum of ultrastructural changes 
of cell architectonics in MCF-7 cells of different sub-
lines and apoptotic death of higher numbers of cells.
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